Hikma Pharmaceuticals PLC (OTCPK:HKMPY) Shareholder/Analyst Call November 6, 2025 4:30 AM EST
Company Participants
Riad Mishlawi – Interim Head of Injectables Business, CEO & Director
Khalid Nabilsi – Chief Financial Officer
Conference Call Participants
Zain Ebrahim – JPMorgan Chase & Co, Research Division
Charlie Haywood – BofA Securities, Research Division
Christian Glennie – Stifel, Nicolaus & Company, Incorporated, Research Division
Victor Floch – BNP Paribas, Research Division
Beatrice Fairbairn – Joh. Berenberg, Gossler & Co. KG, Research Division
Kane Slutzkin – Deutsche Bank AG, Research Division
James Vane-Tempest – Jefferies LLC, Research Division
Sebastien Jantet – Panmure Liberum Limited, Research Division
Miles Dixon – Peel Hunt LLP, Research Division
Presentation
Operator
Good day, ladies and gentlemen, and welcome to Hikma November 2025 Trading Update.
[Operator Instructions]
I will now hand over to Investor Relations for opening remarks. Please go ahead.
Unknown Executive
Thank you. Before we start, we’d like to remind you that any forward-looking statements or projections made by Hikma during this call are made in good faith based on information currently available and subject to risks and uncertainties that may cause actual results to differ materially from those projected. For further information, please see the Principal Risks and Uncertainties section in Hikmas’s latest annual report. And with that, let me hand over to our CEO, Riad Mishlawi.
Riad Mishlawi
Interim Head of Injectables Business, CEO & Director
Many thanks. Good morning, everyone, and thank you for all joining this call regarding our November trading update that we have published this morning. Before we come to your questions, I want to briefly cover a handful of key points in the update. Firstly, the business is performing well, and we are on track to meet our 2025 guidance. It is really encouraging to see all 3 businesses doing well. Secondly, we know that there is a key focus on the injectable margins. We have always achieved industry-leading margins
